• Billy small

    Izun CEO, Dr. William Levine, speaks at Dutch Periodontal Society annual meeting

    Dr William Levine, founder and CEO of Izun Pharmaceuticals, was the featured speaker at the annual meeting of the Dutch Periodontal Society. The meeting, which took place outside of Amsterdam in November 2013, was attended by the overwhelming majority of all periodontists in Holland. Dr. Levine introduced new treatment paradigms for controlling periodontal inflammation and

    Read More February 13, 2014
  • Izun Pharmaceuticals Corporation Announces a Development Project with Ducere Pharma LLC

    Izun Pharmaceuticals Corporation, an emerging pharmaceutical company in New York which focuses on developing high efficacy botanical pharmaceutical products, announced a strategic alliance for the US and Canadian markets with Ducere Pharma LLC, a privately owned healthcare company that markets innovative consumer healthcare products under well recognized brand names. The alliance will combine Izun’s patented

    Read More December 19, 2013
  • izunpharmaceuticals

    Expansion of Phase II Clinical Trial

    Izun Pharmaceuticals Corporation recently announced that it has expanded its ongoing Phase II clinical trial assessing the effect of its novel drug candidate, IZN-6N4, on Oral Mucositis (OM) to two additional medical centers, Memorial Sloan-Kettering Cancer Center and Beth Israel Medical Center, a component of the Continuum Cancer Centers of New York. The studies are

    Read More July 17, 2013
  • PerioPatch-Box-izunpharma

    PerioPatch Receives Excellent Market Reviews

    Izun Pharmaceuticals is proud to announce that PerioPatch was reviewed by Dr. Gordon Christensen’s Clinical Research Group. The patch was independently reviewed by selected research clinicians in a dental office environment by testing on their own patients. The clinicians were requested to assess efficacy and functionality in a clinical office setting, and patient response, as part

    Read More April 21, 2013
  • PeriActive-Izunpharma

    PeriActive™: Another breakthrough trial

    PeriActive™ was evaluated in a randomized multi-center, open label clinical trial for use in post-implant surgery. Patients undergoing dental implant surgery used either PeriActive™ or Chlorhexidine mouthrinse for 1 month following surgery. The effects of the rinses were compared with respect to reducing bacterial plaque, as well as to reducing inflammation and improving healing in the surgical site. Chlorhexidine

    Read More March 11, 2013
  • Women’s Health Care

    Izun Pharmaceuticals has established a new project team to expand into a significant and inadequately addressed therapeutic area in Women’s Health care, Atrophic Vaginitis (AV). This condition develops in women experiencing a drop in estrogen levels. AV occurs in 50% of post- menopausal women and develops in most women undergoing treatment for breast cancer.

    Read More January 6, 2013
  • FDA approval of Phase II clinical trial

    Izun was granted approval by the FDA to enter into a Phase II clinical trial of IZN-6N4, its product for the prevention and treatment of Oral Mucositis (OM). OM, a side effect of radiation and/or chemotherapy, is characterized by ulceration of the oral cavity, causing patients to suffer from infection, intense pain and malnutrition.

    Read More July 11, 2012
  • Izun nominates Mr. Oscar Schafer to the Izun board

    Mr. Schafer is the Managing Partner of O.S.S. Capital Management LP, a private investment partnership which he co-founded in 2001. A well-respected Wall Street professional, he has been a longtime participant in the Barron’s Roundtable of top money managers. Previously, Mr. Schafer was a Member of Cumberland Associates  and, prior to that, was a General Partner at

    Read More May 31, 2012
  • Izun nominates Dr Elliot Hahn as Executive Director

    Dr. Elliot F. Hahn was appointed to the position of executive director of Izun. Dr. Hahn is also the Executive Chairman of Accu-Break Pharmaceuticals, Inc., a privately held company.  He co-founded Andrx Corporation and was Chairman Emeritus and a Director of Andrx until its acquisition by Watson Pharmaceuticals, Inc. in November 2006 for $1.9 billion.

    Read More May 29, 2012